Page 32 - SAHCS HIVMed Journal Vol 20 No 1 2019
P. 32

Page 3 of 26  Guideline


              TABLE 1: Causes of death at post-mortem examination of 39 HIV-infected patients of the Charlotte Maxeke Johannesburg Academic Hospital, January–December 2009. 9
              Causes of death by        All deaths (N = 39)  Pre-ART deaths (N = 14)  Early-ART deaths (N = 15)  Late-ART deaths (N = 10)
              category and/or organism†
                                        n         %         n         %         n         %         n         %
              Mycobacterial            27.0       69        8         57        13        87        6         60
              Bacterial                13.0       33        5         36        6         40        2         20
              Fungal                    8.2       21        3         21        4         27        1         10
              Viral, not HIV            3.0       8         2         14        0         0         1         10
              Neoplasm                 10.0       26        3         21        3         20        4         40
              Organ dysfunction‡       10.0       26        1         7         5         33        4         40
              IRIS                     11.0       28        -         -         11        73        -          -
              Diagnosis unsuspected at death§  19.0  49     7         50        8         53        4         40
              Unexplained               5.0       13        4         29        1         7         0         0
              Source: Wong EB, Omar T, Setlhako GJ, et al. Causes of death on antiretroviral therapy: A post-mortem study from South Africa. PLoS One. 2012;7(10):e47542. https://doi.org/10.1371/journal.
              pone.0047542
              ART, antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome.
              Note: Categorised by the duration of ART at the time of death. Pre-ART deaths occurred in patients who were HIV-positive and eligible for ART but had not yet received it (CD4 cell count < 200 cells/
                3
              mm ) or those who had received < 7 days of ART. Early ART deaths occurred between 7 and 90 days of ART. Late ART deaths occurred after > 90 days of ART.
              †, All causes of death (immediate and contributing) are included and each patient may have ≥ 1 cause of death.
              ‡, Non-infectious organ dysfunction, that is, pulmonary embolism or end-stage renal disease.
              §, At least one cause of death was revealed only through the post-mortem investigation.
              TABLE 2: Guidelines for the management of acute pain at the end of life.  38
              Type of pain and treatment  Initial dosage       Comment
              Mild-to-moderate pain
              Acetaminophen       1000 mg orally or rectally 3–4 times a day  Do not exceed 4 g per day. Use with caution in the presence of liver disease, particularly in
              (Paracetamol)                                    the elderly and with concomitant alcohol use.
              Ibuprofen (NSAIDS)  800 mg orally 3–4 times a day  GIT upset and bleeds, ulceration; Avoid in renal failure and use with caution in the presence
                                                               of liver disease
              Codeine             30 mg with/without 325 mg acetaminophen   Do not exceed 360 mg per day. Note that constipation is usual. Provide advice regarding diet,
                                  orally every 3–4 h as needed  exercise and the use of laxatives. Codeine can be addictive and thus should be used under
                                                               supervision.
              Oxycodone           5 mg with or without 325 mg acetaminophen,   If analgesia is inadequate with initial treatment, adjust the dosage to 10 mg orally every 3–4
                                  orally every 3–4 h as needed  h as needed. As it can be addictive, use under supervision.
              Moderate-to-severe pain in patients not already on opioids
              Morphine            Oral: 2 mg – 4 mg every 30–60 min as needed  For both morphine and hydromorphone, if analgesia is inadequate with initial treatment,
                                  IV: 2 mg – 5 mg every 15–30 min as needed  increase the bolus dose by 25% – 50% for moderate pain or by 50% – 100% for severe pain.
                                                               Morphine can be addictive and thus should be used under supervision.
              Hydromorphone       Oral: 2 mg – 4 mg every 30 min as needed  If the level of analgesia is acceptable, administer continuous infusion (equal to the total daily
                                  IV: 0.4 mg – 0.8 mg every 15–30 min as   opioid dose) over 24 h, with a breakthrough dose every hour equivalent to 10% – 20% of the
                                  required                     total 24 h opioid dose. If the current drug causes unacceptable side effects, administer an
                                                               equianalgesic dose of a different opioid. As it can be addictive, use under supervision.
              Moderate-to-severe pain in patients already on opioids
              Morphine/Hydromorphone  Bolus dose, up to 10% – 20% of total opioid   If previously satisfactory analgesia becomes inadequate, increase the basal and bolus dose by
                                  taken in the previous 24 h, every 15–60 min as   25% – 50% for moderate pain and by 50% – 100% for severe pain.
                                  needed                       For daily follow-up, calculate the total 24 h dose received, i.e., basal + breakthrough, and
                                                               adjust the basal rate to equal this 24 h opioid amount; Adjust the bolus dose to 10% – 20%
                                                               of this 24 h total. If the current drug causes unacceptable side effects, administer an
                                                               equianalgesic dose of a different opioid.
              Neuropathic pain
              Opioids             Adjust dose until analgesia has been achieved  -
              Glucocorticoids     For example, 4 mg – 16 mg dexamethasone IV   Consider especially for acute neurologic injury such as nerve or spinal cord compression from
                                  daily                        a tumour.
              Transdermal lidocaine patches  -                 Consider especially when allodynia is present.
              Short-acting antiepileptic drug, for  -          If survival of more than a few days is anticipated, consider adding one of these agents
              example, gabapentin, pregabalin or               immediately.
              tricyclic antidepressant
              Source: Blinderman CD, Billings JA. Comfort care for patients dying in the hospital. N Eng J Med. 2015;373:2549–2561. https://doi.org/10.1056/NEJMra1411746
              NSAIDS, non-steroidal anti-inflammatory drugs.
              epidemic  are  interlinked.  Uncontrolled  plasma  (HIV)  viral   inconsistent  data collection, the huge rural–urban divide,
              load increases the  risk of malignancy.  AIDS-defining   empty drug shelves and constant drug stockouts, et cetera.
              malignancies were described in the 1980s and 1990s but are   This section  briefly  reviews  this subject.  Answers to the
              still widespread throughout sub-Saharan Africa today. In the   palliation of HIV-related cancer include greater access to
              era of  ART, the risk of non-AIDS defining cancers is also   prevention, for example, vaccination against the Human
              increasing. Universal Test and Treat (UTT) and the 90-90-90   Papilloma Virus (HPV) and the broader reach of cervical
              by 2020 initiatives of the WHO and the UNAIDS, will help to
              reduce risk in the long term if successful.           health assessments in women, vaccination against Hepatitis
                                                                    B and the improved early diagnosis of cancer and the rapid
              However, at this time, oncology and radiotherapy on the   referral  to  cancer  curative  treatment  services.  Closer
              African continent face multiple challenges: poor and ageing   collaboration  between  Africa’s  oncologists,  radiotherapists
              infrastructure, insufficient numbers of skilled professionals,   and HIV clinicians is needed if any of this is to be achieved.

                                           http://www.sajhivmed.org.za  25  Open Access
   27   28   29   30   31   32   33   34   35   36   37